M. Barbieri, M. Bonafè, C. Franceschi, and G. Paolisso, Insulin/IGF-I-signaling pathway: An evolutionarily conserved mechanism of longevity from yeast to humans, Am. J. Physiol, vol.285, pp.1064-1071, 2003.

Q. Fu, X. Yu, C. W. Callaway, R. H. Lane, and R. A. Mcknight, Epigenetics: Intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene, FASEB J, vol.23, pp.2438-2449, 2009.

A. M. Oberbauer, The regulation of IGF-1 gene transcription and splicing during development and aging, Front. Endocrinol, vol.4, p.39, 2013.

J. Yang, M. Anzo, and P. Cohen, Control of aging and longevity by IGF-I signaling, Exp. Gerontol, vol.40, pp.867-872, 2005.

A. Bartke, Healthspan and longevity can be extended by suppression of growth hormone signaling, Mamm. Genome, vol.27, pp.289-299, 2016.

Y. Suh, G. Atzmon, M. Cho, D. Hwang, B. Liu et al., Functionally significant insulin-like growth factor I receptor mutations in centenarians, Proc. Natl. Acad. Sci. U.S.A, vol.105, pp.3438-3442, 2008.

J. Guevara-aguirre, P. Balasubramanian, M. Guevara-aguirre, M. Wei, F. Madia et al., Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans, Sci. Transl. Med, vol.3, pp.70-83, 2011.

S. Milman, G. Atzmon, D. M. Huffman, J. Wan, J. P. Crandall et al., Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity, Aging Cell, vol.13, pp.769-771, 2014.

A. Besson, S. Salemi, S. Gallati, A. Jenal, R. Horn et al.,

, J. Clin. Endocrinol. Metab, vol.88, pp.3664-3667, 2003.

C. Höybye and J. S. Christiansen, Growth hormone replacement in adults-Current standards and new perspectives, Best Pract. Res. Clin. Endocrinol. Metab, vol.29, pp.115-123, 2015.

A. Bartke, Pleiotropic effects of growth hormone signaling in aging, Trends Endocrinol. Metab, vol.22, pp.437-442, 2011.

E. Van-der-spoel, S. W. Jansen, A. A. Akintola, B. E. Ballieux, C. M. Cobbaert et al., Growth hormone secretion is diminished and tightly controlled in humans enriched for familial longevity, Aging Cell, vol.15, pp.1126-1131, 2016.

P. J. Godowski, D. W. Leung, L. R. Meacham, J. P. Galgani, R. Hellmiss et al., Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism, Proc. Natl. Acad. Sci. U.S.A, vol.86, pp.8083-8087, 1989.

A. A. Palizban, M. Radmansorry, and M. Bozorgzad, Exon 3-deleted and full-length growth hormone receptor polymorphism frequencies in an Iranian population, Res. Pharm. Sci, vol.9, pp.489-494, 2014.

J. Pantel, K. Machinis, M. Sobrier, P. Duquesnoy, M. Goossens et al., Speciesspecific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution, J. Biol. Chem, vol.275, pp.18664-18669, 2000.

C. Santos, L. Essioux, C. Teinturier, M. Tauber, V. Goffin et al., A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone, Nat. Genet, vol.36, pp.720-724, 2004.

A. A. Jorge, F. G. Marchisotti, L. R. Montenegro, L. R. Carvalho, B. B. Mendonca et al., Growth hormone (GH) pharmacogenetics: Influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency, J. Clin. Endocrinol. Metab, vol.91, pp.1076-1080, 2006.

G. Binder, F. Baur, R. Schweizer, and M. B. Ranke, The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children, J. Clin. Endocrinol. Metab, vol.91, pp.659-664, 2006.

L. Audi, C. Esteban, A. Carrascosa, R. Espadero, A. Pérez-arroyo et al., Exon 3-deleted/fulllength growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA, J. Clin. Endocrinol. Metab, vol.91, pp.5038-5043, 2006.

A. G. Renehan, M. Solomon, M. Zwahlen, R. Morjaria, A. Whatmore et al., Growth hormone receptor polymorphism and growth hormone therapy response in children: A Bayesian meta-analysis, Am. J. Epidemiol, vol.175, pp.867-877, 2012.

M. J. Wassenaar, O. M. Dekkers, A. M. Pereira, J. M. Wit, J. W. Smit et al., Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: A systematic review and meta-analysis, J. Clin. Endocrinol. Metab, vol.94, pp.3721-3730, 2009.

M. Zoledziewska, C. Sidore, C. W. Chiang, S. Sanna, A. Mulas et al.,

S. Uzzau, C. Jones, R. Lyons, A. Angius, G. R. Abecasis et al., Height-reducing variants and selection for short stature in Sardinia, Nat. Genet, vol.47, pp.1352-1356, 2015.

M. B. Lanktree, Y. Guo, M. Murtaza, J. T. Glessner, S. D. Bailey et al.,

H. Watkins-on-behalf-of, S. F. Procardis, P. B. Grant, K. E. Munroe, N. J. North et al.,

N. Soranzo, G. A. Fitzgerald, A. Reiner, R. A. Hegele, H. Hakonarson et al., Meta-analysis of dense genecentric association studies reveals common and uncommon variants associated with height, Meena Kumari on behalf of the Whitehall II Study and the WHII 50K Group, vol.88, pp.6-18, 2011.

P. Bougnères, The exon-3 deletion of the growth hormone receptor (GHR) gene still has a limited impact in clinical endocrinology, J. Clin. Endocrinol. Metab, vol.95, pp.56-59, 2010.

J. Pantel, J. Grulich-henn, M. Bettendorf, C. J. Strasburger, U. Heinrich et al., Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform, J. Clin. Endocrinol. Metab, vol.88, pp.1705-1710, 2003.

R. J. Strawbridge, L. Kärvestedt, C. Li, S. Efendic, C. G. Östenson et al., GHR exon 3 polymorphism: Association with type 2 diabetes mellitus and metabolic disorder, Growth Horm. IGF Res, vol.17, pp.392-398, 2007.

M. Ouni, A. Castell, A. Linglart, and P. Bougnères, Genetic and epigenetic modulation of growth hormone sensitivity studied with the IGF-1 generation test, J. Clin. Endocrinol. Metab, vol.100, pp.919-925, 2015.

P. C. Tapia, R. Rhoa, and . Kinase, JAK2, and STAT3 may be the intracellular determinants of longevity implicated in the progeric influence of obesity: Insulin, IGF-1, and leptin may all conspire to promote stem cell exhaustion, Med. Hypotheses, vol.66, pp.570-576, 2006.

M. Rincon, R. Muzumdar, G. Atzmon, and N. Barzilai, The paradox of the insulin/IGF-1 signaling pathway in longevity, Mech. Ageing Dev, vol.125, pp.397-403, 2004.

S. W. Park, S. Lee, Y. B. Sohn, S. H. Kim, S. Cho et al., A polymorphism in the growth hormone receptor is associated with height in children with Prader-Willi syndrome, Am. J. Med. Genet. A, vol.155, pp.2970-2973, 2011.

R. Tacutu, T. Craig, A. Budovsky, D. Wuttke, G. Lehmann et al., Human Ageing Genomic Resources: Integrated databases and tools for the biology and genetics of ageing, Nucleic Acids Res, vol.41, pp.1027-1033, 2013.

V. D. Longo and C. E. Finch, Evolutionary medicine: From dwarf model systems to healthy centenarians?, Science, vol.299, pp.1342-1346, 2003.

C. Finch, The Biology of Human Longevity: Inflammation, Nutrition, and Aging in the Evolution of Lifespans, 2007.

P. Anversa, Aging and longevity: The IGF-1 enigma, Circ. Res, vol.97, pp.411-414, 2005.

A. Bartke, Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice, Neuroendocrinology, vol.78, pp.210-216, 2003.

M. Bonafè, M. Barbieri, F. Marchegiani, F. Olivieri, E. Ragno et al., Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: Cues for an evolutionarily conserved mechanism of life span control, J. Clin. Endocrinol. Metab, vol.88, pp.3299-3304, 2003.

E. Van-der, M. P. Spoel, J. J. Rozing, P. E. Houwing-duistermaat, M. Slagboom et al., Association analysis of insulin-like growth factor-1 axis parameters with survival and functional status in nonagenarians of the Leiden Longevity Study, Aging, vol.7, pp.956-963, 2015.

A. J. Brooks and M. J. Waters, The growth hormone receptor: Mechanism of activation and clinical implications, Nat. Rev. Endocrinol, vol.6, pp.515-525, 2010.

C. Giavoli, E. Ferrante, E. Profka, L. Olgiati, S. Bergamaschi et al., Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short-and long-term recombinant human GH replacement therapy, Eur. J. Endocrinol, vol.163, pp.361-368, 2010.

R. S. Jallad, E. B. Trarbach, F. H. Duarte, A. A. Jorge, and M. D. Bronstein, Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly, Pituitary, vol.18, pp.666-673, 2015.

C. A. Glad, L. M. Carlsson, O. Melander, P. Almgren, L. Sjöström et al., The GH receptor exon 3 deleted/full-length polymorphism is associated with central adiposity in the general population, Eur. J. Endocrinol, vol.172, pp.123-128, 2015.

T. Alfred, Y. Ben-shlomo, R. Cooper, R. Hardy, C. Cooper et al., HALCyon Study Team, A multi-cohort study of polymorphisms in the GH/IGF axis and physical capability: The HALCyon programme, PLOS ONE, vol.7, p.29883, 2012.

L. Perice, N. Barzilai, J. Verghese, E. F. Weiss, R. Holtzer et al., Lower circulating insulin-like growth factor-I is associated with better cognition in females with exceptional longevity without compromise to muscle mass and function, Aging, vol.8, pp.2414-2424, 2016.

R. K. Junnila, S. Duran-ortiz, O. Suer, E. G. Sustarsic, D. E. Berryman et al., Disruption of the GH receptor gene in adult mice increases maximal lifespan in females, Endocrinology, vol.157, pp.4502-4513, 2016.

P. A. Parsons, Antagonistic pleiotropy and the stress theory of aging, Biogerontology, vol.8, pp.613-617, 2007.

A. Rajwani, V. Ezzat, J. Smith, N. Y. Yuldasheva, E. R. Duncan et al., Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis, Diabetes, vol.61, pp.915-924, 2012.

C. H. Waddington, The Strategy of Genes, 1957.

J. M. Lancaster, M. E. Carney, and P. A. , BRCA 1 and 2-A genetic link to familial breast and ovarian cancer, Medscape Womens Health, vol.2, p.7, 1997.

G. Atzmon, I. Gabriely, W. Greiner, D. Davidson, C. Schechter et al., Plasma HDL levels highly correlate with cognitive function in exceptional longevity, J. Gerontol., Ser. A, vol.57, pp.712-715, 2002.

G. Atzmon, C. Schechter, W. Greiner, D. Davidson, G. Rennert et al., Clinical phenotype of families with longevity, J. Am. Geriatr. Soc, vol.52, pp.274-277, 2004.

N. Barzilai, G. Atzmon, C. Schechter, E. J. Schaefer, A. L. Cupples et al., Unique lipoprotein phenotype and genotype associated with exceptional longevity, JAMA, vol.290, pp.2030-2040, 2003.

G. Atzmon, M. Rincon, C. B. Schechter, A. R. Shuldiner, R. B. Lipton et al., Lipoprotein genotype and conserved pathway for exceptional longevity in humans, PLOS Biol, vol.4, p.113, 2006.

J. Verghese, R. B. Lipton, C. B. Hall, G. Kuslansky, M. J. Katz et al., Abnormality of gait as a predictor of non-Alzheimer's dementia, N. Engl. J. Med, vol.347, pp.1761-1768, 2002.

L. P. Fried, N. O. Borhani, P. Enright, C. D. Furberg, J. M. Gardin et al., The Cardiovascular Health Study: Design and rationale, Ann. Epidemiol, vol.1, pp.263-276, 1991.

J. Wan, G. Atzmon, D. Hwang, N. Barzlai, J. Kratzsch et al., Growth hormone receptor (GHR) exon 3 polymorphism status detection by dual-enzyme-linked immunosorbent assay (ELISA), J. Clin. Endocrinol. Metab, vol.98, pp.77-81, 2013.

J. R. O'connell and D. E. Weeks, PedCheck: A program for identification of genotype incompatibilities in linkage analysis, Am. J. Hum. Genet, vol.63, pp.259-266, 1998.

, were supported by INSERM with additional contribution from Association de Recherche sur le Diabète and an institutional grant from Novo Nordisk France. CHS was supported by contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-55222, N01 HC-15103, N01-HC-75150, and N01-HC-45133; grant number U01 HL080295 from the National Heart, Lung, and Blood Institute; U19 AG023122 from the National Institute on Aging Longevity Consortium; and P30 AG021334 from the National Institute on Aging, Claude D. Pepper Older Americans Independence Centers; and grant R01 HL-071862 (to A.R.), with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of participating CHS investigators and institutions can be, Genotyping services for CHS were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the NIH to the Johns Hopkins University (contract number N01-HG-65403), 2016.

, , 2017.

D. Ben-avraham, D. R. Govindaraju, T. Budagov, D. Fradin, P. Durda et al., The GH receptor exon 3 deletion is a marker of male-specific exceptional longevity associated with increased GH sensitivity and taller stature, Sci. Adv, vol.3, p.1602025, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02320509

D. Gutman, L. Sharvit, R. Kaplan, P. Bougnères, A. Reiner et al., , p.1602025

, Sci Adv REFERENCES

, This article cites 54 articles, 9 of which you can access for free